Bonus BioGroup Ltd. (BBIXF)
USD 0.03
(-41.18%)
USD 0.03
(-41.18%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 15.58 Million ILS | -14.47% |
| 2022 | 18.22 Million ILS | -8.4% |
| 2021 | 19.89 Million ILS | -4.15% |
| 2020 | 20.75 Million ILS | 0.2% |
| 2019 | 20.71 Million ILS | 55.31% |
| 2018 | 13.33 Million ILS | 11.49% |
| 2017 | 11.96 Million ILS | 16.59% |
| 2016 | 10.25 Million ILS | 43.58% |
| 2015 | 7.14 Million ILS | 82.32% |
| 2014 | 3.91 Million ILS | 128.91% |
| 2013 | 1.71 Million ILS | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 16.62 Million ILS | -1.5% |
| 2024 Q1 | 16.87 Million ILS | 8.28% |
| 2023 Q4 | 15.58 Million ILS | 0.93% |
| 2023 Q2 | 15.91 Million ILS | -7.78% |
| 2023 Q3 | 15.44 Million ILS | -3.0% |
| 2023 FY | 15.58 Million ILS | -14.47% |
| 2023 Q1 | 17.26 Million ILS | -5.27% |
| 2022 Q1 | 18.74 Million ILS | -5.78% |
| 2022 FY | 18.22 Million ILS | -8.4% |
| 2022 Q4 | 18.22 Million ILS | 9.76% |
| 2022 Q3 | 16.6 Million ILS | -9.63% |
| 2022 Q2 | 18.37 Million ILS | -1.98% |
| 2021 Q3 | 19.7 Million ILS | 265.83% |
| 2021 FY | 19.89 Million ILS | -4.15% |
| 2021 Q2 | 5.38 Million ILS | -69.26% |
| 2021 Q1 | 17.51 Million ILS | -15.59% |
| 2021 Q4 | 19.89 Million ILS | 0.97% |
| 2020 Q4 | 20.75 Million ILS | -11.77% |
| 2020 FY | 20.75 Million ILS | 0.2% |
| 2020 Q3 | 23.52 Million ILS | 2.03% |
| 2020 Q2 | 23.05 Million ILS | 1.16% |
| 2020 Q1 | 22.78 Million ILS | 10.03% |
| 2019 Q4 | 20.71 Million ILS | 3.76% |
| 2019 Q2 | 18.99 Million ILS | 1.42% |
| 2019 Q1 | 18.73 Million ILS | 40.47% |
| 2019 FY | 20.71 Million ILS | 55.31% |
| 2019 Q3 | 19.96 Million ILS | 5.06% |
| 2018 Q2 | 13.78 Million ILS | 7.44% |
| 2018 FY | 13.33 Million ILS | 11.49% |
| 2018 Q4 | 13.33 Million ILS | 6.23% |
| 2018 Q1 | 12.82 Million ILS | 7.24% |
| 2018 Q3 | 12.55 Million ILS | -8.91% |
| 2017 Q1 | 11.23 Million ILS | 9.53% |
| 2017 Q3 | 11.01 Million ILS | 1.29% |
| 2017 Q4 | 11.96 Million ILS | 8.59% |
| 2017 FY | 11.96 Million ILS | 16.59% |
| 2017 Q2 | 10.87 Million ILS | -3.22% |
| 2016 Q2 | 8.98 Million ILS | 8.41% |
| 2016 Q1 | 8.28 Million ILS | 16.01% |
| 2016 FY | 10.25 Million ILS | 43.58% |
| 2016 Q4 | 10.25 Million ILS | 0.91% |
| 2016 Q3 | 10.16 Million ILS | 13.13% |
| 2015 Q2 | 5.03 Million ILS | 21.79% |
| 2015 Q1 | 4.13 Million ILS | 5.38% |
| 2015 FY | 7.14 Million ILS | 82.32% |
| 2015 Q4 | 7.14 Million ILS | 9.47% |
| 2015 Q3 | 6.52 Million ILS | 29.76% |
| 2014 Q4 | 3.91 Million ILS | 64.87% |
| 2014 Q2 | 2.07 Million ILS | 56.12% |
| 2014 Q1 | 1.33 Million ILS | -22.25% |
| 2014 FY | 3.91 Million ILS | 128.91% |
| 2014 Q3 | 2.37 Million ILS | 14.39% |
| 2013 Q3 | 1.61 Million ILS | -5.56% |
| 2013 FY | 1.71 Million ILS | 0.0% |
| 2013 Q2 | 1.7 Million ILS | 12.66% |
| 2013 Q4 | 1.71 Million ILS | 6.07% |
| 2013 Q1 | 1.51 Million ILS | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Qrons Inc. | 1.48 Million USD | -946.81% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 73.593% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -1826.819% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -7648.762% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 68.996% |
| BioStem Technologies, Inc. | 15.9 Million USD | 2.016% |
| CSL Limited | 18.62 Billion USD | 99.916% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -64.633% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 78.496% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 79.199% |
| Regen BioPharma, Inc. | 5.45 Million USD | -185.546% |
| Skye Bioscience, Inc. | 14.07 Million USD | -10.743% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -34766.655% |
| Rebus Holdings, Inc. | 5.24 Million USD | -197.291% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -56707.495% |
| Neon Bloom, Inc. | 1.22 Million USD | -1170.905% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 70.764% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -62.638% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -3596.675% |
| SQZ Biotechnologies Company | 50.03 Million USD | 68.856% |
| Intellipharmaceutics International Inc. | 12 Million USD | -29.772% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -304.63% |
| Mesoblast Limited | 188.44 Million USD | 91.73% |
| Marizyme, Inc. | 26.67 Million USD | 41.58% |
| Genus plc | 485 Million USD | 96.787% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -166.73% |
| Pharming Group N.V. | 244.07 Million USD | 93.615% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -675.273% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -519.315% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -310.105% |
| ContraFect Corporation | 32.53 Million USD | 52.095% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -686.551% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -307.143% |
| IMV Inc. | 37.93 Million USD | 58.917% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -32.312% |
| MultiCell Technologies, Inc. | 1617.67 USD | -963260.883% |
| ONE Bio Corp. | 27.49 Million USD | 43.322% |
| Accustem Sciences Inc. | 1.07 Million USD | -1343.98% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 79.87% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -636.808% |
| Q BioMed Inc. | 8.13 Million USD | -91.616% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 81.209% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -202.835% |
| Biomind Labs Inc. | 1.49 Million USD | -939.896% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 86.874% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -72.348% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 15.32% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -986.856% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -10867.311% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -171.223% |
| GB Sciences, Inc. | 5.41 Million USD | -187.657% |
| Alpha Cognition Inc. | 7.16 Million USD | -117.509% |
| HST Global, Inc. | 593.59 Thousand USD | -2525.368% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1137.618% |
| Halberd Corporation | 728.71 Thousand USD | -2038.547% |
| Enzolytics Inc. | 365.26 Million USD | 95.734% |
| Agentix Corp. | 2.51 Million USD | -520.739% |
| Resverlogix Corp. | 67.39 Million USD | 76.877% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -1758.043% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 96.498% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -809.218% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 37.024% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -30.924% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -325.192% |
| AVAX Technologies, Inc. | 3.99 Million USD | -290.21% |
| Zenith Capital Corp. | 27.56 Thousand USD | -56427.259% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.825% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -6429.956% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -317.32% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2188.957% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -474.707% |
| Kadimastem Ltd | 3.5 Million USD | -344.639% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -23184.376% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -3253.569% |
| LadRx Corporation | 2.2 Million USD | -608.194% |
| Cell Source, Inc. | 15.8 Million USD | 1.409% |
| Regen BioPharma, Inc. | 5.45 Million USD | -185.546% |
| NovAccess Global Inc. | 7.86 Million USD | -98.251% |
| Affymax, Inc. | 8.87 Million USD | -75.674% |
| Itoco Inc. | 1.65 Million USD | -842.685% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -659.615% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -157.629% |
| Mobile Lads Corp. | 1.31 Million USD | -1086.451% |
| CytoDyn Inc. | 127.89 Million USD | 87.815% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -37183.189% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -894.907% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -41.092% |
| SYBLEU INC | 681.41 Thousand USD | -2187.012% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -155.396% |
| International Stem Cell Corporation | 5.27 Million USD | -195.319% |
| Bioxytran, Inc. | 3.24 Million USD | -379.581% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2390.217% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -237.526% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 61.987% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 30.007% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -669.433% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -184.483% |
| Neutra Corp. | 973.52 Thousand USD | -1500.774% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 46.29% |
| PureTech Health plc | 125.58 Million USD | 87.591% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -314.785% |
| IXICO plc | 1.9 Million USD | -720.084% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 24.088% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 84.917% |
| CSL Limited | 18.62 Billion USD | 99.916% |
| Cellectis S.A. | 249.36 Million USD | 93.751% |